SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis

Annexin A7 (ANXA7) is a suppressor of tumorigenesis and metastasis in prostate Cancer. Activated ANXA7 GTPase promotes prostate Cancer cell Apoptosis. However, the role and underlying mechanism of ANXA7 GTPase in prostate Cancer metastasis have not been established. RKIP is a metastatic suppressor and downregulated in prostate Cancer metastases. The binding of RKIP and its target proteins could inhibit the activation of its interactive partners. However, the effect of RKIP on ANXA7 GTPase activation is not clear. Here, we report that activation of ANXA7 GTPase by a small molecule SEC ((S)-ethyl 1-(3-(4-chlorophenoxy)-2-hydroxypropyl)-3- (4-methoxyphenyl)-1H-pyrazole-5-carboxylate) effectively inhibited prostate Cancer metastasis. Mechanistically, activated ANXA7 promoted AMPK phosphorylation, leading to decreased mTORC1 activity, suppressed STAT3 nuclear translocation, and downregulation of pro-metastatic genes, including CCL2, APLN, and IL6ST. Conversely, RKIP interacted with ANXA7 and impaired activation of ANXA7 GTPase by SEC and its downstream signaling pathway. Notably, SEC treatment suppressed metastasis of prostate Cancer cells in in vivo orthotopic analysis. Together, our findings provide a novel insight into how metastasis of prostate Cancer with low RKIP expression is suppressed by SEC-induced activation of ANXA7 GTPase via the AMPK/mTORC1/STAT3 signaling pathway.